Inga-Malin Simek

Inga-Malin Simek

Auto-generated profile, based on publicly available information

Inga-Malin Simek

Medical University of Vienna, Department of Radiation Oncology, Vienna, Austria; Christian Doppler Laboratory for Image and Knowledge Driven Precision Radiation Oncology, Medical University of Vienna, Vienna, Austria

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 November 2023 in Physics and Imaging in Radiation Oncology
Verified
Journal Article
Open access
Gerd HeilemannGerd Heilemann
Gerd Heilemann
MBMartin Buschmann
Martin Buschmann
WLWolfgang Lechner
Wolfgang Lechner
VDVincent Dick
Vincent Dick
FEFranziska Eckert
Franziska Eckert
PTPetra Trnkova
Petra Trnkova
Tools for auto-segmentation in radiotherapy are widely available, but guidelines for clinical implementation are missing. The goal was to develop a workflow for performance evaluation of three commercial auto-segmentation tools to select one candidate for clinical implementation. One hundred patients with six treatment sites (brain, head-and-neck, thorax, abdomen, and pelvis) were included. Three sets of AI-based contours for organs-at-risk (OAR) generated by three software tools and manually drawn expert contours were blindly rated for contouring accuracy. The dice similarity coefficient (DSC), the Hausdorff distance, and a dose/volume evaluation based on the recalculation of the original treatment plan were assessed. Statistically significant differences were tested using the Kruskal-Wallis test and the post-hoc Dunn Test with Bonferroni correction. The mean DSC scores compared to expert contours for all OARs combined were 0.80 ± 0.10, 0.75 ± 0.10, and 0.74 ± 0.11 for the three software tools. Physicians' rating identified equivalent or superior performance of some AI-based contours in head (eye, lens, optic nerve, brain, chiasm), thorax (e.g., heart and lungs), and pelvis and abdomen (e.g., kidney, femoral head) compared to manual contours. For some OARs, the AI models provided results requiring only minor corrections. Bowel-bag and stomach were not fit for direct use. During the interdisciplinary discussion, the physicians' rating was considered the most relevant. A comprehensive method for evaluation and clinical implementation of commercially available auto-segmentation software was developed. The in-depth analysis yielded clear instructions for clinical use within the radiotherapy department.

17 September 2024 in Strahlentherapie und Onkologie
Verified
Journal Article
Open access
PDF file
ISI.-M. Simek
I.-M. Simek
ASAlina E. Sturdza
Alina E. Sturdza
JKJohannes Knoth
Johannes Knoth
ASAndreas Spannbauer
Andreas Spannbauer
JBJutta Bergler-Klein
Jutta Bergler-Klein
MSMaximilian Schmid
Maximilian Schmid
Purpose: Cardiac metastasis from cervical cancer is rare and only scarcely documented. We aim to present a new case and systematically summarize the available literature. Materials and methods: PubMed, Scopus, Web of Science, Central, and ClinicalTrials.gov were systematically searched following the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) criteria. Results were screened via title, abstract, and full text. Additionally, the reference lists of all papers chosen for the review were screened. Results: Eighty-one papers were identified, describing 86 cases in total. Cardiac metastasis occurred at all stages of cervical cancer and in all age groups. Median time from initial diagnosis to diagnosis of cardiac metastasis was 12 months. Patients mainly complained of dyspnea and chest pain, 60.8% had pathologic ECG (electrocardiographic) findings. The cardiac mass was most frequently detected by transthoracic echography. The most common tumor histology was squamous cell carcinoma. Chemotherapy and surgical interventions were the main treatment modalities. Median survival after diagnosis of cardiac metastasis was 3 months. Conclusion: This largest review on cardiac metastases from cervical cancer confirmed the heart as a very infrequent site of metastasis. There are < 100 cases described in the literature, with very poor prognosis and undefined clinical management.

25 November 2025 in Radiotherapy and Oncology
Verified
Journal Article
Open access
LZLukas Zimmermann
Lukas Zimmermann
BKBarbara Knäusl
Barbara Knäusl
JKJohannes Knoth
Johannes Knoth
ASAlina E. Sturdza
Alina E. Sturdza
VDVincent Dick
Vincent Dick
MSMaximilian Schmid
Maximilian Schmid
Accurate gross tumor volume (GTV) delineation is critical for successful radiochemotherapy and image-guided adaptive brachytherapy (BT) in cervical cancer. This study investigated whether diffusion-weighted imaging (DWI) improves GTV delineation accuracy compared to T2-weighted (T2w) MRI alone, across different physician experience levels. Twenty-seven patients with locally advanced cervical carcinoma undergoing primary radiochemotherapy were analyzed. Six physicians (three experts, three residents) delineated GTVs at three time points: diagnosis (init), pre-brachytherapy (preBT), and pre-brachytherapy with applicator in situ (BT). Segmentations were performed using T2w images alone and T2w plus DWI (b=800smm-2) guidance. Expert consensus served as reference standard using STAPLE algorithm. Inter-observer agreement was assessed using conformity index, Dice-Sørensen coefficient, and Hausdorff distance. DWI guidance significantly improved inter-observer agreement among experts at init (conformity index: 0.62→ 0.70, p<0.05) and BT (0.33→ 0.39, p<0.05) time points. For residents, DWI guidance enhanced agreement with expert consensus, particularly during BT, with significant improvements in Dice coefficient (median increase 9%, p<0.05) and reduced Hausdorff distance (median decrease 1.3 mm, p<0.05). Tumor volume correlation between preBT and BT time points improved with DWI guidance for both groups. Incorporating DWI into the segmentation workflow reduces inter-observer variability for both expert and resident radiation oncologists. DWI guidance particularly benefits less experienced physicians, enabling them to achieve contours closer to expert consensus standards through additional functional information.

21 January 2024 in Clinical and Translational Radiation Oncology
Verified
Journal Article
Open access
JWJoachim Widder
Joachim Widder
ISInga-Malin Simek
Inga-Malin Simek
GGGregor M. Goldner
Gregor M. Goldner
Gerd HeilemannGerd Heilemann
Gerd Heilemann
JUJan F. Ubbels
Jan F. Ubbels
To further personalise treatment in metastatic cancer, the indications for metastases-directed local therapy (MDT) and the biology of oligometastatic disease (OMD) should be kept conceptually apart. Both need to be vigorously investigated. Tumour growth dynamics - growth rate combined with metastatic seeding efficiency - is the single most important biological feature determining the likelihood of success of MDT in an individual patient, which might even be beneficial in slowly developing polymetastatic disease. This can be reasonably well assessed using appropriate clinical imaging. In the context of considering appropriate indications for MDT, detecting metastases at the edge of image resolution should therefore suggest postponing MDT. While three to five lesions are typically used to define OMD, it could be argued that countability throughout the course of metastatic disease, rather than a specific maximum number of lesions, could serve as a better parameter for guiding MDT. Here we argue that the unit of MDT as a treatment option in metastatic cancer might best be defined not as a single procedure at a single point in time, but as a series of treatments that can be delivered in a single or multiple sessions to different lesions over time. Newly emerging lesions that remain amenable to MDT without triggering the start of a new systemic treatment, a change in systemic therapy, or initiation of best supportive care, would thus not constitute a failure of MDT. This would have implications for defining endpoints in clinical trials and registries: Rather than with any disease progression, failure of MDT would only be declared when there is progression to polymetastatic disease, which then precludes further options for MDT.

29 December 2023 in Clinical and Translational Radiation Oncology
Verified
Journal Article
Open access
RBRenee Bultijnck
Renee Bultijnck
MHMieke Van Hemelrijck
Mieke Van Hemelrijck
VFValérie Fonteyne
Valérie Fonteyne
LLLorenzo Livi
Lorenzo Livi
BJBarbara Alicja Jereczek-Fossa
Barbara Alicja Jereczek-Fossa
POPiet Ost
Piet Ost
Objective: To evaluate the impact of metastases -directed stereotactic body radiotherapy (SBRT) on health -related quality of life (HRQoL) in men with oligometastatic prostate cancer (PCa) using real -world data from the OligoCare cohort. Materials and methods: OligoCare is a pragmatic, observational cohort designed to assess the impact of metastases -directed SBRT on patients with oligometastatic disease (OMD). We report an interim analyses of the secondary endpoint HRQoL, assessed using the EORTC QLQ-C30, within six months of metastases -directed SBRT for oligometastatic disease in men with PCa among the first 1600 registered patients. HRQoL data collection was optional within the OligoCare cohort. To compare HRQoL between baseline and first follow-up assessment, a Wilcoxon signed -rank test was used. A multiple linear regression model was used to explore the HRQoL associations with predefined factors. Results: Out of the 1600 registered patients, 658 were treated for oligometastatic PCa, of which 233 had baseline QoL data and 132 patients had both baseline and follow-up HRQoL data. At baseline, most patients had a WHO performance status of 0 or 1 (87 %), were de-novo oligometastatic (79 %), had one metastasis (90 %), and had a good overall global health status (mean 80.81, SD16.11, IQR 75-92). 51 % received hormonal therapy as concomitant systemic treatment. Patients with comorbidities as assessed by the Charlson Comorbidity index had a worse global health status at baseline (-4.88, 95 % CI: -9.35, -0.42). No clinically meaningful significant difference in global health status was observed at first assessment following SBRT (median 3.0 months) compared with baseline (mean difference 2.27, 95 % CI: -1.54, 6.08). Upon evaluating the proportions, meaningful clinically important differences (a 10 -point or more difference) was observed in, 17 % and 11 % of the patients reporting deterioration and improvement of global health status, respectively. Conclusion: Metastases -directed stereotactic body radiotherapy had no negative impact on global HRQoL within the first six months after treatment.

24 September 2026 in Strahlentherapie und Onkologie
Verified
Journal Article
Open access
PDF file
ISI. M. Simek
I. M. Simek
SPS. Piroty-Dehbokry
S. Piroty-Dehbokry
JWJoachim Widder
Joachim Widder
RSR. Schmid
R. Schmid
JKJohannes Knoth
Johannes Knoth
Purpose: Definitive chemoradiotherapy is the standard treatment for anal cancer, but the optimal management of small (T1) tumours remains unclear, as these tumours are underrepresented in prospective trials. Methods: We retrospectively analysed all patients with T1 anal carcinoma treated with curative intent at the Medical University of Vienna between 1990 and 2022. Patient, tumour, and treatment characteristics were extracted. Outcomes included overall survival (OS), disease-free survival (DFS), colostomy-free survival (CFS), and acute and late toxicity. Kaplan–Meier estimates, log-rank tests, and univariable Cox regression were used for exploratory time-to-event analyses. Results: Fifty-five patients (median age 67 years, range 31–86; female/male ratio 2.4:1) were included. The median prescribed dose was 58 Gy; 45% received concurrent chemotherapy and 35% a brachytherapy boost. Five-year OS, DFS, and CFS were 84.7%, 80.1%, and 85.3%, respectively. Late grade 3 toxicity occurred in six patients (11%), exclusively after 2D/3D radiotherapy. No statistically significant OS or DFS differences were demonstrated for brachytherapy, chemotherapy, nodal involvement, or IMRT/VMAT in exploratory univariable analyses. Conclusions: Patients with T1 anal carcinoma achieved favourable long-term tumour control and organ preservation after definitive radiotherapy or chemoradiotherapy. Severe late toxicity was observed only after 2D/3D radiotherapy; however, concurrent changes in treatment technique, dose, target volumes, and treatment era preclude attribution of this observation to any single treatment component. Numerically favourable outcomes with brachytherapy and concurrent chemotherapy were observed, but these findings remain hypothesis-generating and require validation in prospective studies.